Honz Pharmaceutical Co., Ltd. (300086) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Honz Pharmaceutical Co., Ltd.

Why is Honz Pharmaceutical Co., Ltd. ?

With a Operating Losses, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Net Sales has grown by an annual rate of -13.21% and Operating profit at -242.72% over the last 5 years
High Debt Company with a Debt to Equity ratio (avg) at times

The company has declared Negative results for the last 5 consecutive quarters

PRE-TAX PROFIT(Q) At CNY -51.22 MM has Fallen at -113.26%
NET PROFIT(Q) At CNY -42.53 MM has Fallen at -94.49%
ROCE(HY) Lowest at -16.53%

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 61.87%, its profits have fallen by -48.2%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Honz Pharmaceutical Co., Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Honz Pharmaceutical Co., Ltd.

58.71%

1.76

72.14%

China Shanghai Composite

15.17%

1.02

14.86%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-13.21%

EBIT Growth (5y)

-242.72%

EBIT to Interest (avg)

-2.46

Debt to EBITDA (avg)

31.18

Net Debt to Equity (avg)

0.37

Sales to Capital Employed (avg)

0.33

Tax Ratio

3.46%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

0.44%

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.97

EV to EBIT

-24.71

EV to EBITDA

-49.05

EV to Capital Employed

2.44

EV to Sales

7.67

PEG Ratio

Dividend Yield

ROCE (Latest)

-9.87%

ROE (Latest)

-14.06%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

7What is working for the Company

OPERATING CASH FLOW(Y)

Highest at CNY 123.34 MM

NET PROFIT(HY)

Higher at CNY -86.92 MM

RAW MATERIAL COST(Y)

Fallen by -38.54% (YoY

-24What is not working for the Company

PRE-TAX PROFIT(Q)

At CNY -51.22 MM has Fallen at -113.26%

NET PROFIT(Q)

At CNY -42.53 MM has Fallen at -94.49%

ROCE(HY)

Lowest at -16.53%

DEBT-EQUITY RATIO (HY)

Highest at 44.61 %

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.21 times

INTEREST(Q)

At CNY 4.37 MM has Grown at 16.22%

CASH AND EQV(HY)

Lowest at CNY 65.41 MM

NET SALES(Q)

Lowest at CNY 93.93 MM

OPERATING PROFIT(Q)

Lowest at CNY -46.77 MM

OPERATING PROFIT MARGIN(Q)

Lowest at -49.79 %

Here's what is working for Honz Pharmaceutical Co., Ltd.

Operating Cash Flow

Highest at CNY 123.34 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Raw Material Cost

Fallen by -38.54% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Honz Pharmaceutical Co., Ltd.

Net Sales

At CNY 93.93 MM has Fallen at -32.97%

Year on Year (YoY)

MOJO Watch

Near term sales trend is extremely negative

Net Sales (CNY MM)

Pre-Tax Profit

At CNY -51.22 MM has Fallen at -113.26%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (CNY MM)

Net Profit

At CNY -42.53 MM has Fallen at -94.49%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (CNY MM)

Interest

At CNY 4.37 MM has Grown at 16.22%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Debt-Equity Ratio

Highest at 44.61 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Inventory Turnover Ratio

Lowest at 1.21 times and Fallen

In each half year in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Net Sales

Lowest at CNY 93.93 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (CNY MM)

Operating Profit

Lowest at CNY -46.77 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (CNY MM)

Operating Profit Margin

Lowest at -49.79 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Cash and Eqv

Lowest at CNY 65.41 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents